Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William A Denny

Showing results (1-10 of 237) with videos related to

Pageof 24
Sort By:
Future Medicinal Chemistry|April 13, 2021
Inhibitors of F<sub>1</sub>F<sub>0</sub>-ATP synthase enzymes for the treatment of tuberculosis and cancerWilliam A Denny
Journal of Biomedicine & Biotechnology|April 11, 2003
Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)William A. Denny
Idrugs : the Investigational Drugs Journal|December 1, 2004
American Association for Cancer Research - 93rd Annual Meeting. Investigational kinase inhibitors. 6-10 April 2002, San Francisco, CA, USAWilliam A Denny
Pharmaceuticals (Basel, Switzerland)|February 26, 2022
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer TherapyWilliam A Denny
Current Medicinal Chemistry|August 13, 2002
Acridine derivatives as chemotherapeutic agentsWilliam A Denny
Cancer Investigation|November 30, 2004
Tumor-activated prodrugs--a new approach to cancer therapyWilliam A Denny
Idrugs : the Investigational Drugs Journal|April 2, 2004
EdotecarinWilliam A Denny
Expert Opinion on Therapeutic Patents|March 16, 2013
Phosphoinositide 3-kinase α inhibitors: a patent reviewWilliam A Denny
Current Cancer Drug Targets|February 16, 2022
Inhibitors and Activators of the p38 Mitogen-Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and InflammationWilliam A Denny
Expert Opinion on Emerging Drugs|May 25, 2004
Emerging DNA topisomerase inhibitors as anticancer drugsWilliam A Denny
Pageof 24

Showing results (1-10 of 237) with videos related to

Sort By:
Pageof 24
Future Medicinal Chemistry|April 13, 2021
Inhibitors of F<sub>1</sub>F<sub>0</sub>-ATP synthase enzymes for the treatment of tuberculosis and cancerWilliam A Denny
Journal of Biomedicine & Biotechnology|April 11, 2003
Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)William A. Denny
Idrugs : the Investigational Drugs Journal|December 1, 2004
American Association for Cancer Research - 93rd Annual Meeting. Investigational kinase inhibitors. 6-10 April 2002, San Francisco, CA, USAWilliam A Denny
Pharmaceuticals (Basel, Switzerland)|February 26, 2022
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer TherapyWilliam A Denny
Current Medicinal Chemistry|August 13, 2002
Acridine derivatives as chemotherapeutic agentsWilliam A Denny
Cancer Investigation|November 30, 2004
Tumor-activated prodrugs--a new approach to cancer therapyWilliam A Denny
Idrugs : the Investigational Drugs Journal|April 2, 2004
EdotecarinWilliam A Denny
Expert Opinion on Therapeutic Patents|March 16, 2013
Phosphoinositide 3-kinase α inhibitors: a patent reviewWilliam A Denny
Current Cancer Drug Targets|February 16, 2022
Inhibitors and Activators of the p38 Mitogen-Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and InflammationWilliam A Denny
Expert Opinion on Emerging Drugs|May 25, 2004
Emerging DNA topisomerase inhibitors as anticancer drugsWilliam A Denny
Pageof 24